Account
Inquiry
QSC Tirzepatide (LY3298176) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes research. This synthetic peptide demonstrates superior efficacy in glucose control and weight management compared to selective GLP-1 receptor agonists.
The qsc tirzepatide compound exhibits greater affinity for GIP receptors while maintaining significant activity at GLP-1 receptors. This unique dual mechanism of action results in enhanced reduction of hyperglycemia in research models. The molecular structure of qsc tirzepatide allows it to effectively mimic the actions of natural GIP at the GIP receptor.
Our qsc tirzepatide is supplied as a high purity white powder with pharmaceutical grade quality. The product undergoes rigorous HPLC testing to ensure consistent quality and purity standards for research applications. Proper storage at controlled temperatures maintains the stability of qsc tirzepatide for extended periods.
Research studies indicate that qsc tirzepatide not only enhances β-cell function but also reduces glucagon secretion through α-cell modulation. These combined effects contribute to reduced hepatic glucose output and improved metabolic parameters in experimental models.
